ESTA

Business Context and Reporting Period

Company: Establishment Labs Holdings Inc. (ESTA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Establishment Labs is a medical technology company focused on breast aesthetics and reconstruction, primarily through its Motiva Implants. The company manufactures products in Costa Rica and sells globally. A pivotal milestone occurred in September 2024 when the company received FDA Premarket Approval (PMA) for Motiva Implants, allowing commercial sales in the United States beginning in October 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased slightly by 0.5% ($0.8 million) to $166.0 million. This was driven by a 43% increase in Asia-Pacific revenue and new North American sales following FDA approval, partially offset by a 28% decline in Latin America (primarily Brazil).
• Profitability: Net loss widened to $84.6 million from $78.5 million. The increase in loss was primarily due to a $6.0 million non-cash contract termination cost and an $8.8 million foreign currency transaction loss (compared to a gain in 2023).
• Operating Expenses: Total operating expenses decreased by $12.5 million (7.3%). Research and Development (R&D) expenses dropped significantly by 25.4% to $19.7 million due to reduced personnel costs and lower IDE clinical trial expenditures. SG&A expenses decreased by 4.0% to $139.8 million.
• Liquidity: Cash balances more than doubled to $90.3 million, bolstered by $99.5 million in net proceeds from equity offerings in January and November 2024 and a $25 million drawdown on the Tranche C Term Loan.

Guidance, Outlook, and Risks

• Outlook: Management expects an uptick in overall operating expenses in fiscal 2025 relative to 2024 due to intensified commercial and operational efforts post-FDA approval. The company does not expect to be profitable in 2025.
• Recent Developments:
  • Launched "Preservé," a minimally invasive breast tissue-preserving technology, in Brazil in February 2025.
  • CEO Juan José Chacón-Quirós announced retirement effective March 1, 2025; President Peter Caldini will serve as Interim CEO.
  • Completed construction of a new 100,000 sq. ft. manufacturing facility in Costa Rica, increasing capacity by ~730,000 units/year.
• Key Risks:
  • Profitability: The company expects to incur losses for the foreseeable future and relies on the commercial success of Motiva Implants to achieve profitability.
  • Supply Chain: Reliance on a single-source supplier (Avantor) for medical-grade silicone, the primary raw material.
  • Regulatory & Safety: Risks associated with the medical device industry, including potential product recalls, litigation regarding breast implant safety (e.g., BIA-ALCL), and regulatory compliance.
  • Currency: Significant exposure to foreign currency fluctuations, particularly the Brazilian Real and Euro, which impacted 2024 results.

Investor Verification Checklist

• US Market Penetration: Verify the actual sales volume and market share capture in the United States following the October 2024 launch, as this is a primary growth driver.
• Latin America Demand: Assess the sustainability of the 28% revenue decline in Latin America and the impact of macroeconomic conditions in Brazil.
• Debt Covenants: Review the Credit Agreement terms, specifically the gross sales thresholds required to access the remaining Tranche D Term Loan ($25 million) and the impact of interest rates (9-10%).
• Leadership Transition: Monitor the execution of the business strategy under the new Interim CEO and the potential impact of the CEO transition on operations.
• Contract Termination Costs: Confirm the nature and final settlement of the $6.0 million contract termination cost recorded in Q4 2024 related to Mia products in Europe.